Your browser is no longer supported. Please, upgrade your browser.
PIRS Pieris Pharmaceuticals, Inc. daily Stock Chart
Pieris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own0.22% Shs Outstand52.37M Perf Week-20.21%
Market Cap123.77M Forward P/E- EPS next Y-0.74 Insider Trans-94.16% Shs Float52.35M Perf Month-26.38%
Income-14.70M PEG- EPS next Q-0.12 Inst Own67.70% Short Float3.59% Perf Quarter-30.86%
Sales56.90M P/S2.18 EPS this Y-10.90% Inst Trans-5.93% Short Ratio3.73 Perf Half Y11.48%
Book/sh0.89 P/B2.62 EPS next Y-57.40% ROA-11.80% Target Price- Perf Year-59.55%
Cash/sh1.45 P/C1.60 EPS next 5Y- ROE-35.00% 52W Range1.60 - 5.97 Perf YTD-35.64%
Dividend- P/FCF- EPS past 5Y-10.70% ROI-52.80% 52W High-61.64% Beta1.18
Dividend %- Quick Ratio5.00 Sales past 5Y53.90% Gross Margin- 52W Low43.12% ATR0.23
Employees114 Current Ratio5.00 Sales Q/Q111.30% Oper. Margin-22.40% RSI (14)31.07 Volatility11.15% 7.63%
OptionableYes Debt/Eq0.00 EPS Q/Q60.40% Profit Margin-25.90% Rel Volume2.21 Prev Close2.33
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume503.82K Price2.29
Recom1.50 SMA20-18.85% SMA50-21.47% SMA200-24.72% Volume221,488 Change-1.72%
Mar-13-20Upgrade Robert W. Baird Neutral → Outperform $5
Jul-30-19Downgrade Robert W. Baird Outperform → Neutral
May-14-19Initiated Robert W. Baird Outperform $5
Mar-19-18Initiated Jefferies Buy $12
Mar-19-18Initiated Evercore ISI Outperform $13
Jan-16-18Reiterated H.C. Wainwright Buy $9 → $12
May-30-17Initiated Rodman & Renshaw Buy $9
Aug-05-16Resumed ROTH Capital Buy
Aug-12-15Initiated JMP Securities Mkt Outperform
Jul-27-15Initiated Oppenheimer Outperform $8
Jul-22-15Initiated ROTH Capital Buy $7
Sep-20-20 11:00AM  
Sep-03-20 04:30PM  
Aug-12-20 12:45PM  
Aug-10-20 08:10AM  
Aug-04-20 11:13AM  
Aug-03-20 08:00AM  
Jul-28-20 11:34AM  
Jul-23-20 08:00AM  
Jul-22-20 10:22AM  
Jul-21-20 07:27PM  
Jul-20-20 04:05PM  
Jun-23-20 11:51AM  
Jun-08-20 04:30PM  
May-28-20 08:00AM  
May-14-20 10:23AM  
May-11-20 09:55AM  
May-04-20 08:00AM  
May-01-20 12:30PM  
Apr-28-20 08:42AM  
Mar-30-20 11:11AM  
Mar-24-20 04:23PM  
Mar-23-20 04:30PM  
Mar-14-20 10:52AM  
Mar-12-20 07:00AM  
Mar-09-20 12:30PM  
Mar-05-20 08:00AM  
Feb-25-20 08:00AM  
Jan-20-20 10:52AM  
Jan-08-20 08:00AM  
Dec-19-19 06:29PM  
Dec-05-19 03:49AM  
Dec-04-19 09:42AM  
Nov-27-19 11:07PM  
Nov-19-19 09:56AM  
Nov-17-19 08:42AM  
Nov-15-19 08:00AM  
Nov-14-19 08:00AM  
Nov-11-19 01:55PM  
Nov-09-19 12:00PM  
Nov-07-19 08:00AM  
Nov-06-19 03:40AM  
Nov-05-19 08:00AM  
Nov-04-19 08:00AM  
Oct-24-19 04:34AM  
Oct-02-19 11:22AM  
Sep-26-19 09:35AM  
Sep-03-19 07:30AM  
Aug-29-19 08:00AM  
Aug-27-19 07:28PM  
Aug-01-19 07:00AM  
Jul-29-19 02:23PM  
Jul-25-19 08:00AM  
Jul-11-19 01:58PM  
Jun-23-19 04:32PM  
Jun-12-19 12:16PM  
May-31-19 08:40AM  
May-30-19 08:00AM  
May-22-19 02:30PM  
May-14-19 08:00AM  
May-10-19 07:00AM  
May-03-19 08:00AM  
May-02-19 10:33AM  
Apr-28-19 09:20AM  
Apr-03-19 08:50AM  
Apr-02-19 08:00AM  
Apr-01-19 06:25PM  
Mar-12-19 07:00AM  
Mar-06-19 08:00AM  
Mar-05-19 08:00AM  
Feb-26-19 07:45AM  
Feb-21-19 01:22PM  
Jan-09-19 02:40PM  
Dec-21-18 10:45AM  
Dec-17-18 10:44PM  
Dec-04-18 02:24PM  
Nov-27-18 08:15AM  
Nov-14-18 09:46PM  
Nov-09-18 04:22PM  
Nov-08-18 08:00AM  
Nov-07-18 09:00AM  
Oct-31-18 08:00AM  
Oct-25-18 08:16AM  
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aquilo Capital Management, LLC10% OwnerJul 21Sale2.951,900,0005,605,0003,675,530Jul 22 06:15 PM